Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.52 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18480825 | 1.00 | MASP2 (0.55) | MASP2NPY5RSCN2ASSTR1PDE10A | |
| Hydrochloric Acid SCHEMBL18438992 | 0.98 | MASP2 (0.53) | MASP2NPY5RSCN2ASSTR1PDE10A | |
| SCHEMBL18480460 | 0.86 | MASP2 (0.51) | MASP2NPY5RSCN2ASSTR1PDE10A | |
| SCHEMBL6757627 | 0.85 | NPY5R (0.55) | MASP2NPY5RSCN2ASSTR1PDE10A | |
| Hydrochloric Acid SCHEMBL18438825 | 0.85 | MASP2 (0.50) | MASP2NPY5RSCN2ASSTR1PDE10A | |
| SCHEMBL16355448 | 0.84 | SCN10A (0.41) | — | |
| SCHEMBL19323265 | 0.83 | TRPV1 (0.44) | MASP2 | |
| SCHEMBL20900024 | 0.83 | EGFR (0.46) | — | |
| SCHEMBL20900023 | 0.83 | EGFR (0.46) | — | |
| SCHEMBL9912151 | 0.81 | NLN (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659075-A | Preparation and application of imidazole derivative type column [5] arene chiral filler | 中国科学院兰州化学物理研究所 | 2024-03-08 | — | — | CN | claimed |
| CN-106636246-B | Biological method for preparing (S) -1- (5-phenyl-1H-imidazole-2-yl) ethylamine | 尚科生物医药（上海）有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-117659075-A | Preparation and application of imidazole derivative type column [5] arene chiral filler | 中国科学院兰州化学物理研究所 | 2024-03-08 | — | — | CN | disclosed |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220056073-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | UNIV CORNELL (US) | 2022-02-24 | — | — | US | disclosed |
| US-11203613-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY | 2021-12-21 | — | — | US | disclosed |
| US-20200317729-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | CORNELL UNIVERSITY | 2020-10-08 | — | — | US | disclosed |
| EP-3694605-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | Cornell University (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-106636246-B | Biological method for preparing (S) -1- (5-phenyl-1H-imidazole-2-yl) ethylamine | 尚科生物医药（上海）有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-106636246-B | Biological method for preparing (S) -1- (5-phenyl-1H-imidazole-2-yl) ethylamine | 尚科生物医药（上海）有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-106636246-B | Biological method for preparing (S) -1- (5-phenyl-1H-imidazole-2-yl) ethylamine | 尚科生物医药（上海）有限公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019075252-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019075252-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
| CN-106636246-A | Preparation of (S)-1-(5-phenyl-1H-imidazol-2-yl)ethylamine through biological method | 尚科生物医药（上海）有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106636246-A | Preparation of (S)-1-(5-phenyl-1H-imidazol-2-yl)ethylamine through biological method | 尚科生物医药（上海）有限公司 | 2017-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317729-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | PSMB1, PSMB3, PSMB11 | MASP2 759/4885NPY5R 1175/4885SCN2A 4141/4885 |
| US-20220056073-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | PSMB1, PSMB3, PSMB11 | MASP2 726/4885NPY5R 1202/4885SCN2A 4132/4885 |
| US-11203613-B2 | Peptidomimetic proteasome inhibitors | PSMB1, PSMB3, PSMB11 | MASP2 759/4885NPY5R 1175/4885SCN2A 4141/4885 |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | PSMB1, PSMB3, PSMB11 | MASP2 726/4885NPY5R 1202/4885SCN2A 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.